New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
14:43 EDTILMN, AMGNIllumina February volatility up, shares at record high on agreement with Amgen
Illumina (ILMN) February call option implied volatility is at 40, March is at 36, June is at 35; compared to its 26-week average of 35 according to Track Data, suggesting large near term price movement on an agreement with Amgen (AMGN) to develop oncology companion diagnostic test.
News For ILMN;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 21, 2014
13:56 EDTAMGNDan Loeb discloses position in Amgen at Robin Hood Conference, CNBC reports
Subscribe for More Information
12:57 EDTILMNOn The Fly: Midday Wrap
Subscribe for More Information
10:00 EDTILMNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:15 EDTILMNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Apple (AAPL), up 3%... Texas Instruments (TXN), up 2.3%... Harley Davidson (HOG), up 7%... Celanese (CE), up 4%... United Technologies (UTX), up 1.4%. ALSO HIGHER: Neonode (NEON), up 20% after signing technology development agreement with global tier-one printer OEM... Illumina (ILMN), up 10%, upgraded at Janney Capital following the company's better than expected Q3 earnings. DOWN AFTER EARNINGS: Coca-Cola (KO), down 5%... Chipotle (CMG), down 4.6%... Verizon (VZ), down 1%. ALSO LOWER: CEL-SCI (CVM), down 15.3% after announcing proposed offering of common stock, warrants... Omeros (OMER), down 12% after suspending Huntington's clinical trial with OMS824... Tesoro Logistics (TLLP), down 2.4% after 20M share secondary priced at $57.47... Rhino Resources (RNO), down 53%, downgraded to Underperform at Raymond James following the reduction in its quarterly cash dividend.
07:52 EDTILMNIllumina upgraded to Buy at Janney Capital
As reported previously, Janney Capital upgraded Illumina to Buy from Neutral citing its Q3 earnings beat and checks indicating next generation sequencing competition remains sidelined as the company's competition focuses on diagnostics. Janney raised its fair value estimate on the stock to $192 from $165.
07:22 EDTILMNIllumina upgraded to Buy from Neutral at Janney Capital
Subscribe for More Information
07:15 EDTAMGNFDA to hold workshop on breast cancer drug development
Subscribe for More Information
06:16 EDTILMNIllumina price target raised to $210 from $192 at Piper Jaffray
Piper Jaffray raised its price target for Illumina shares to $210 following the company's better than expected Q3 results and increased guidance. Piper views the new guidance as achievable and keeps an Overweight rating on the stock.
October 20, 2014
18:51 EDTILMNOn The Fly: After Hours Movers
Subscribe for More Information
16:51 EDTILMNIllumina up 9.8% after reporting Q3 results
Subscribe for More Information
16:13 EDTILMNIllumina trades higher after results, first look
Subscribe for More Information
16:11 EDTILMNIllumina raises FY14 EPS view to $2.63-$2.65, consensus $2.30
Raises FY14 revenue growth view to approximately 30% YoY, consensus $1.8B. Prior view was $2.26-$2.28 for EPS and 25%-26% for revenue growth. Cites strong year to date results.
16:09 EDTILMNIllumina reports Q3 gross margin 69.5% vs. 58.8% in prior year period
Subscribe for More Information
16:09 EDTILMNIllumina reports Q3 adjusted EPS 77c, consensus 56c
Subscribe for More Information
15:30 EDTILMNNotable companies reporting after market close
Subscribe for More Information
07:19 EDTAMGNIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTILMNAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTILMNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 19, 2014
15:56 EDTAMGNAmgen to aid in production method for Ebola drug ZMapp, Bloomberg says
Subscribe for More Information
October 17, 2014
09:06 EDTAMGNAmgen files patent infringement lawsuit against Sanofi, Regeneron
Amgen (AMGN) announced that it filed a lawsuit in the United States District Court of Delaware against Sanofi (SNY), Aventisub, formerly doing business as Aventis Pharmaceuticals, and Regeneron Pharmaceuticals (REGN) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, or PCSK9. By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S. Amgen previously announced submission of a Biologics License Application to the FDA for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use